GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » FCF Yield %

Reshape Lifesciences (Reshape Lifesciences) FCF Yield % : -317.62 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Reshape Lifesciences's Trailing 12-Month Free Cash Flow is $-14.01 Mil, and Market Cap is $4.41 Mil. Therefore, Reshape Lifesciences's FCF Yield % for today is -317.62%.

The historical rank and industry rank for Reshape Lifesciences's FCF Yield % or its related term are showing as below:

RSLS' s FCF Yield % Range Over the Past 10 Years
Min: -2329.37   Med: -351.86   Max: -26.15
Current: -317.62


During the past 13 years, the highest FCF Yield % of Reshape Lifesciences was -26.15%. The lowest was -2329.37%. And the median was -351.86%.

RSLS's FCF Yield % is ranked worse than
97.59% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: -2.775 vs RSLS: -317.62

Reshape Lifesciences's FCF Margin % for the quarter that ended in Mar. 2024 was -106.58%.


Reshape Lifesciences FCF Yield % Historical Data

The historical data trend for Reshape Lifesciences's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences FCF Yield % Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -53.78 -629.60 -290.29

Reshape Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -297.80 -524.39 -952.82 -167.79 -191.61

Competitive Comparison of Reshape Lifesciences's FCF Yield %

For the Medical Devices subindustry, Reshape Lifesciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's FCF Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's FCF Yield % falls into.



Reshape Lifesciences FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Reshape Lifesciences's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-17.003 / 5.85723787
=-290.29%

Reshape Lifesciences's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-2.072 * 4 / 4.32548924
=-191.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reshape Lifesciences FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Reshape Lifesciences FCF Yield % Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (Reshape Lifesciences) Business Description

Traded in Other Exchanges
N/A
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey director, officer: President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy director 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney director 2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney director 2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford director 7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald officer: Chief Retail Officer C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt officer: Vice President of Marketing C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr 10 percent owner 467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022

Reshape Lifesciences (Reshape Lifesciences) Headlines